• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Positive Phase 3 results for ciclesonide nasal aerosol for perennial allergic rhinitis

Sunovion is presenting results from a 26-week double-blind, randomized Phase 3 study of ciclesonide HFA nasal aerosol involving more than 1,100 patients with perennial allergic rhinitis (PAR) that showed statistically significant improvement in nasal symptoms for ciclesonide compared to placebo. The study demonstrated positive results for both a 74 mcg dose and a 148 mcg dose. Nycomed, which licensed US development, marketing, and commercialization rights to ciclesonide to Sunovion in 2008, filed an NDA for the ciclesonide nasal aerosol with a proposed dose of 74 mcg in June 2011.

Lead investigator William E. Berger, Clinical Professor, Department of Pediatrics, University of California, Irvine said, “Perennial allergic rhinitis has a significant effect on millions of people nationwide and researchers and industry are committed to developing new and innovative treatment options to address a wide variety of patient needs. We are encouraged by these findings from this Phase 3 study in PAR patients investigating ciclesonide nasal aerosol in an HFA propellant.”

“We are pleased to see results for ciclesonide nasal aerosol in patients with PAR that are similar to those previously seen in patients with seasonal allergic rhinitis (SAR). These results support our development program for ciclesonide nasal aerosol and underscore our company’s commitment to developing treatments for patients suffering from respiratory ailments,” commented Sunovion VP of Clinical Development and Medical Affairs Alistair Wheeler.

Read the Sunovion press release.

Share

published on November 7, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews